Navigation Links
RxISK Seeks Reports from AbbVie Customers as part of campaign launched today by Dr. David Healy

Toronto, Canada (PRWEB) July 15, 2013, the first free independent website for researching and reporting prescription drug side effects, is helping a campaign to capture patient reported side effects of a range of drugs sold by the pharmaceutical company AbbVie - the recent spun-off entity of Abbott Laboratories.

The campaign was announced by Dr. David Healy, a leading drug safety advocate and psychopharmacologist, in his recent blog post on

As reported in the PharmaTimes May 1, 2013, AbbVie and InterMune sued the European Medicines Agency (EMA) to prevent the release of data and obtained an interim injunction to prevent the release. Bloomberg reports July 12, 2013, that this interim decision is being appealed by EMA.

(Interim decision see C-389/13 P, EMA v. AbbVie, C-390/13 P, EMA v. InterMune U.K. and Others.)

"Since most drugs are marketed and used globally this data could have global significance," says Dr. Healy. Healy is among the growing group of high profile advocates for access to complete data.

Dr. Healy says, “data transparency would be an important first step in helping patients and their doctors make informed decisions on the benefits and risks of prescription medicines by enabling independent validation. We urge everyone to make their voices heard on this issue”.

“Side effects know no borders and in this campaign we want to use to collect patient reports about their experiences on AbbVie drugs from every corner of the planet. We will share these results with everyone – including AbbVie,” says Healy.

AbbVie drugs include:
Kaletra (for HIV/AIDs)
Androgrel (for low Testosterone)
Lupron used (for prostate cancer, breast cancer and endometriosis)

RxISK — your megaphone to help change drug safety allows users to enter the name of a prescription drug and see the side effects that have been reported to the FDA since 2004, as well as to RxISK, for more than 35,000 drug names from 103 countries. The data is presented in tables, tag clouds, heat maps, and interactive graphs, showing what’s happening with other people taking the same drug around the world.

Users can then select the effect(s) they are experiencing and click on Report a Drug Side Effect to complete a report. They get a personalized RxISK Report linking their symptoms and meds, which they can take to their doctor or pharmacist to facilitate a better treatment conversation. This will also add their anonymized experience to the RxISK database so that others can benefit from this information.

About Data Based Medicine Americas Ltd. is owned and operated by Data Based Medicine Americas Ltd. (DBM), based in Toronto, Canada. DBM's founders have international reputations in early drug-side-effect detection and risk mitigation, pharmacovigilance, and patient-centered care. Although drug side effects are known to be a leading cause of death and disability, less than 5% of serious drug side effects are reported. DBM’s mission is to capture this missing data directly from patients through’s free drug side effect reporting tool and use this data to help make medicines safer for all of us.

Media contact
David Carmichael
+1 (647) 799-3792

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1.’s Dr. Healy Coming to Talk to U.S. Audiences About Deadly Prescription Drug Side Effects
2. Special Needs Organization Seeks Parents In Need of a Mentor
3. RundleFit Seeks Promotional Partnership with Socially Responsible, Healthy Lifestyle Brands For Their Six-Week Jump Start/Positive Incentive Program
4. Milaa Event Seeks to Improve a Child’s Academic Learning Through Outdoor Play
5. WEDI Selects Co-Chairs and Seeks Participants for New 2013 WEDI Report Workgroups
6. Announcement: American Garment Manufacturer, Nouvelle, Inc., Seeks Medical and Plastic Surgery Supply Vendors to Distribute USA-Made Compression Wear
7. Bergener & Associates: Woman Who Almost Died After Contracting Hantavirus in June 2012 Seeks Compensation
8. Life Extension Foundation Seeks Volunteers with Alzheimer's to Participate in a Clinical Trial Utilizing a Common Arthritis Drug
9. d’Oliveira & Associates Seeks Clients That Have Been Affected by the Prescription Drug Topamax
10. Eczema Nonprofit Seeks to Shine New Light on Overlooked Condition
11. hCGTreatments / Diet Doc hCG Diet and Weight Loss Plans Seeks Intellectual Property Protection for Their Prescription hCG Diets
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of ... weight gain, cold hands, and dry skin. But many people who find their cholesterol ... exercise regimen instead of their thyroid, especially if they don’t have any of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD and ... of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses ... a dentist in Gettysburg, PA . From routine visits to cosmetic treatments, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety of ... and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ . ... WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during treatment ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
(Date:11/25/2015)... November 25, 2015 --> ... sie eine Lizenz für das Patent über eine neue ... und ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... ins Leben gerufenen und von Edelris gemeinsam mit seinen ... ein Behandlungsziel für HBV identifiziert, und es wurden neue ...
Breaking Medicine Technology: